Targeting immune checkpoint factors, for instance, the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway, has emerged as a durable and prominent therapeutic option in diverse malignancies including NSCLC [10–12]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.